NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: BYR-98833 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Nonalcoholic Steatohepatitis (NASH) Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET

7.1 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 Boehringer Ingelheim

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Cerenis Therapeutics

16.3 Connexios Life Sciences

16.4 Genfit

16.5 Islet Sciences

16.6 Nimbus Therapeutics

16.7 Verva Pharmaceuticals

16.8 Viking Therapeutics

16.9 Astazeneca Plc

16.10 Galmed Pharmaceuticals

16.11 GENFIT SA

16.12 Gilead Science

16.13 Novo Nordisk

16.14 Immuron

16.15 Intercepts Pharmaceuticals

16.16 Enzo Biochem

16.17 Tobira Therapeutics

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

Market By Type
- Weight Loss Treatment
- Insulin-Sensitizing Agents
- Lipid-Lowering Drugs
- Antioxidants
- Others

Based on the end-use, the global Nonalcoholic Steatohepatitis (NASH) market classified into
- Hospitals
- Clinics
- Research Institute
- Others

Companies

Boehringer Ingelheim
Cerenis Therapeutics
Connexios Life Sciences
Genfit
Islet Sciences
Nimbus Therapeutics
Verva Pharmaceuticals
Viking Therapeutics
Astazeneca Plc
Galmed Pharmaceuticals
GENFIT SA
Gilead Science
Novo Nordisk
Immuron
Intercepts Pharmaceuticals
Enzo Biochem
Tobira Therapeutics

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.